Makoto Katoh
Saitama, 3500495, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Imeglimin-Associated Temporal Changes in γ-Glutamyl Transferase and Total Cholesterol: A Post Hoc Exploratory Analysis of the INFINITY Study.
Journal: Journal of personalized medicine
Published: June 30, 2026
Imeglimin Treatment May Improve Whole-Blood Fluidity and Influence Hemorheology in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the INFINITY Study.
Journal: Journal of personalized medicine
Published: April 28, 2026
Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial.
Journal: Frontiers in endocrinology
Published: September 05, 2025
Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study.
Journal: Frontiers in endocrinology
Published: June 28, 2025
Synergistic Effect of Motivation for the Elderly and Support for Going Out II: Measures to Induce Elderly Men to Go Out.
Journal: Geriatrics (Basel, Switzerland)
Published: December 20, 2023
Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Journal: Frontiers in pharmacology
Published: April 14, 2023
Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: March 20, 2023
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Journal: Frontiers in endocrinology
Published: September 12, 2022
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
Journal: Journal of medicinal chemistry
Published: June 02, 2022
Effects of barley intake on glycemic control in Japanese patients with type 2 diabetes mellitus undergoing antidiabetic therapy: a prospective study.
Journal: Diabetology international
Published: July 12, 2021
Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: July 22, 2020
Last Updated: 09/26/2026